140 related articles for article (PubMed ID: 10485271)
1. The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.
Hassan M; Nilsson C; Olsson H; Lundin J; Osterborg A
Eur J Haematol; 1999 Sep; 63(3):163-70. PubMed ID: 10485271
[TBL] [Abstract][Full Text] [Related]
2. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
3. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat.
Hong PS; Srigritsanapol A; Chan KK
Drug Metab Dispos; 1991; 19(1):1-7. PubMed ID: 1673381
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide in cats after oral, intravenous, and intraperitoneal administration of cyclophosphamide.
Stroda KA; Murphy JD; Hansen RJ; Brownlee L; Atencio EA; Gustafson DL; Lana SE
Am J Vet Res; 2017 Jul; 78(7):862-866. PubMed ID: 28650232
[TBL] [Abstract][Full Text] [Related]
6. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.
Sandström M; Freijs A; Larsson R; Nygren P; Fjällskog ML; Bergh J; Karlsson MO
J Clin Oncol; 1996 May; 14(5):1581-8. PubMed ID: 8622075
[TBL] [Abstract][Full Text] [Related]
7. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism.
Busse D; Busch FW; Bohnenstengel F; Eichelbaum M; Fischer P; Opalinska J; Schumacher K; Schweizer E; Kroemer HK
J Clin Oncol; 1997 May; 15(5):1885-96. PubMed ID: 9164199
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cyclophosphamide after oral and intravenous administration to dogs with lymphoma.
Warry E; Hansen RJ; Gustafson DL; Lana SE
J Vet Intern Med; 2011; 25(4):903-8. PubMed ID: 21564295
[TBL] [Abstract][Full Text] [Related]
9. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.
Hassan M; Svensson US; Ljungman P; Björkstrand B; Olsson H; Bielenstein M; Abdel-Rehim M; Nilsson C; Johansson M; Karlsson MO
Br J Clin Pharmacol; 1999 Nov; 48(5):669-77. PubMed ID: 10594468
[TBL] [Abstract][Full Text] [Related]
10. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism.
Busse D; Busch FW; Schweizer E; Bohnenstengel F; Eichelbaum M; Fischer P; Schumacher K; Aulitzky WE; Kroemer HK
Cancer Chemother Pharmacol; 1999; 43(3):263-8. PubMed ID: 9923558
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H;
Hematol J; 2003; 4(4):248-52. PubMed ID: 12872149
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
13. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
J Pharmacokinet Pharmacodyn; 2001 Jun; 28(3):211-30. PubMed ID: 11468938
[TBL] [Abstract][Full Text] [Related]
14. Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high-grade multicentric lymphoma.
Veluvolu S; Willcox JL; Skorupski KA; Al-Nadaf S; Rebhun R; Wittenburg L
Vet Comp Oncol; 2023 Mar; 21(1):20-27. PubMed ID: 36057542
[TBL] [Abstract][Full Text] [Related]
15. Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients.
Hasanah YIF; Harahap Y; Purwanto DJ
Drug Des Devel Ther; 2021; 15():305-313. PubMed ID: 33536743
[TBL] [Abstract][Full Text] [Related]
16. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation.
Fasola G; Lo Greco P; Calori E; Zilli M; Verlicchi F; Motta MR; Ricci P; Baccarani M; Tura S
Haematologica; 1991; 76(2):120-5. PubMed ID: 1937169
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
20. Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.
Hedmer M; Höglund P; Cavallin-Ståhl E; Albin M; Jönsson BA
Int Arch Occup Environ Health; 2008 Jan; 81(3):285-93. PubMed ID: 17579883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
